Loss of smell strongly affects the quality of life in patients with chronic rhinosinusitis (CRS).

Despite a high prevalence in patients with CRS, loss of smell is often under-diagnosed by healthcare providers.

Second-line therapeutic options for smell loss in CRS include systemic corticosteroids and sinonasal surgery.

Given the risk of symptom recurrence and adverse events with second-line treatment options, shared decision-making is important in the management of smell loss.

Monoclonal antibodies targeting type 2 inflammatory signaling pathways have demonstrated effectiveness at improving loss of smell in patients with CRS with nasal polyps (CRSwNP).